Downregulation of TGF-beta receptor types II and III in oral squamous cell carcinoma and oral carcinoma-associated fibroblasts
© Meng et al; licensee BioMed Central Ltd. 2011
Received: 18 August 2010
Accepted: 28 February 2011
Published: 28 February 2011
The purpose of this study was to assess the expression levels for TβRI, TβRII, and TβRIII in epithelial layers of oral premalignant lesions (oral leukoplakia, OLK) and oral squamous cell carcinoma (OSCC), as well as in oral carcinoma-associated fibroblasts (CAFs), with the final goal of exploring the roles of various types of TβRs in carcinogenesis of oral mucosa.
Normal oral tissues, OLK, and OSCC were obtained from 138 previously untreated patients. Seven primary human oral CAF lines and six primary normal fibroblast (NF) lines were established successfully via cell culture. The three receptors were detected using immunohistochemical (IHC), quantitative RT-PCR, and Western blot approaches.
IHC signals for TβRII and TβRIII in the epithelial layer decreased in tissue samples with increasing disease aggressiveness (P < 0.05); no expression differences were observed for TβRI, in OLK and OSCC (P > 0.05); and TβRII and TβRIII were significantly downregulated in CAFs compared with NFs, at the mRNA and protein levels (P < 0.05). Exogenous expression of TGF-β1 led to a remarkable decrease in the expression of TβRII and TβRIII in CAFs (P < 0.05).
This study provides the first evidence that the loss of TβRII and TβRIII expression in oral epithelium and stroma is a common event in OSCC. The restoration of the expression of TβRII and TβRIII in oral cancerous tissues may represent a novel strategy for the treatment of oral carcinoma.
An increasing number of studies demonstrate that transforming growth factor beta (TGF-β) signaling pathway plays a dual role during the initiation and progression of human cancer; initially, it suppresses the formation of tumors, but elevated levels of TGF-β promote the growth, progression, and migration of established tumors. Different explanations have been proposed for this dichotomous function of TGF-β, including the possibility that TGF-β exerts tumor-suppressing effects on epithelial-derived tumor cells and tumor-promoting effects on stromal cells . In general, TGF-β exerts its effect by binding to the TGF-β type II receptor (TβRII) and by subsequently recruiting TβRI for downstream cytoplasmic signaling via multiple parallel signaling pathways, including the SMAD proteins . In addition, TβRIII functions as a coreceptor to increase the binding of ligands to TβRII. In a majority of human cancers and cell lines, the expression of TβRI and TβRII is altered at the protein and/or mRNA levels [3, 4].
The in-depth study of TβRIII revealed that this receptor may have additional functions that are independent of ligand presentation. Ryan et al  showed that the expression of TβRIII (or betaglycan) is downregulated or lost in human prostate cancers compared with benign prostate tissues, at the mRNA and protein levels. Recently, another group used in vitro cell culture and in vivo animal models to demonstrate that the restoration of TβRIII expression in renal cell carcinoma resulted in a marked induction of apoptosis .
Human oral squamous cell carcinoma (OSCC) accounts for about 90% of malignant oral lesions. It is widely recognized as progressing in a multistep manner, with an initial presentation of premalignant lesions (among which oral leukoplakia (OLK) is the most common), and later development of hyperplasia and dysplasia, then in situ carcinoma, and finally invasive carcinoma . However, the expression of the major components of the pathway, which include the systematic analysis of signaling receptors TβRI, TβRII, and TβRIII, remains intact in human OSCC [8, 9]. The current study represents the first systematic analysis of the expression of TβRI, TβRII, and TβRIII during the process of oral epithelial carcinogenesis.
Recent studies strongly suggest that the clinical behavior of malignant tumors not only depends on alterations in the epithelial cells themselves, but is also affected by their interaction with the tumor-associated stroma. However, the components of these specialized stromal cells represent a complex network that includes inflammatory cells (lymphocytes, macrophages, and mast cells), activated fibroblasts, and cells comprising the vasculature. Therefore, it remains questionable whether one single factor will be the "magic bullet" of cancer therapy. Recent data bring prominence to the idea that activated fibroblasts (also termed carcinoma-associated fibroblasts (CAFs) or myofibroblasts) may be major players in the tumor stromal environment [10, 11]. Their role as starting or supportive elements in carcinogenesis is also well established. Relevant studies of modified fibroblasts have been performed in several tumor systems [12, 13]. Some of the systematic and important findings of our previous study suggest that oral CAFs promote the proliferation and invasion of the lingual carcinoma cell line Tca8113 in vitro by secreting the KGF (keratinocyte growth factor) and MMP-2 factors (matrix metalloproteinase) . A recent study showed that TGF-β signaling in fibroblasts modulated the growth and oncogenic potential of adjacent epithelia in selected tissues . Moreover, downregulation of TβRII was observed in colon-carcinoma-associated spindle-like stroma cells that apparently represented fibroblasts and myofibroblasts [14, 16]. In our study, we directly separated and cultured oral CAFs in vitro from adjacent OSCC tissues and evaluated, for the first time, detected the expression levels of the three types of TβRs in oral CAFs.
All surgically resected tissue specimens were obtained from the West China Hospital of Stomatology. For IHC analyses, 138 specimens representing four different clinicopathological stages (including 25 normal epithelium tissues, 21 OLK samples without dysplasia, 24 OLK samples with dysplasia, and 68 infiltrated OSCCs) were recruited from the archives of the Department of Oral Surgery and Oral Medicine. The 138 specimens included eight OSCC samples and paired normal tissues. The corresponding normal tissues were incised along a line that is surgically termed a safety border, which was verified via staining of frozen sections. All surgically resected tissues were collected, fixed in formalin, and embedded in paraffin for histopathological confirmation.
For primary cell cultivation, fresh and sterile tissue specimens (including OSCC and normal oral mucosal tissues) were placed immediately on Hanks Balanced Salt Solution (Gibco, USA) containing penicillin and streptomycin (200 μg/ml) after being collected from the patient. All samples contained the epithelium and adjacent connective tissues. The OSCC specimen was fresh and exhibited infiltration of the adjacent connective tissue. Connective tissues used for sectioning were collected as close as possible to the epithelium. The protocol was reviewed by the Institutional Ethics Committee of Sichuan University and informed consent was obtained from each patient.
Immunostaining for TβRI and TβRII (rabbit polyclonal antibodies; dilution, 1:200; Santa Cruz, USA) and TβRIII (mouse monoclonal antibody; dilution, 1:200; Santa Cruz, USA) in human OSCC and tumor-associated stromal sections was performed using the DakoCytomation EnVision system (DakoCytomation Corporation, Carpinteria, CA), according to the manufacturer's instructions. Slides were counterstained with Modified Harris Hematoxylin. Immunoreactivity was scored as "-" (absent), "1+" (low, ≤ 25% of positive cells), "2+" (moderate, 26-75% of positive cells), or "3+" (diffuse, > 75% of positive cells) . OSCCs were assessed based on at least 10 randomly selected fields. All slides were interpreted by two investigators.
Isolation and Cultivation of Oral CAFs and NFs
The specimens were analyzed using methods described previously. Briefly, tissues were washed twice with phosphate-buffered saline (PBS) and antibiotics. Oral epithelial and adipose tissues were then separated from surrounding stromal cells. The residual connective tissue was cut into small pieces (1 × 1 × 1 mm) that were maintained in Dulbecco's modified Eagle's medium (DMEM, Gibco, USA, pH 7.2) containing 20% fetal calf serum (Gibco, USA), glutamine (20 μg/ml), penicillin (100 U/ml), streptomycin (100 μg/ml), and 0.25% trypsinase (Gibco) at 37°C in an atmosphere containing 5% CO2. To purify the cells, we opted for a method of curettage combined with trypsinization, which was performed when cells covered the bottom of the culture bottle fully. Cultures at passage number three were used for the cellular identification of oral CAFs and NFs. A wide-spectrum α-cytokeratin antibody (ZSGB-BIO, Beijing, Corp., China) was used to confirm the absence of contaminating epithelial cells. Finally, antibodies against vimentin (ZSGB-BIO, Beijing, Corp., China) and smooth muscle α-actin (R&D Systems) were used to confirm the myofibroblastic nature of these cells .
Quantitative Real-Time PCR
Total RNA was isolated from cells using the Trizol reagent (Invitrogen) and was quantified by analysis of absorbance at 260 nm. Relative gene expression levels were calculated using the comparative threshold-cycle method of quantitative PCR, with data normalized to β-actin and expressed relative to untreated controls. Real-time PCR was performed using the SYBR PrimeScript™RT-PCR kit II (TaKaRa, Dalian, China), according to the manufacturer's instructions. The primers used to amplify TβRI, TβRII, and TβRIII were as follows: TβRI sense, 5'-GGTCTTGCCCATCTTCACAT-3' and antisense, 5'-TCTGTGGCTGAATCATGTCT-3'; TβRII sense, 5'-GTCTACTCCATGGCTCTGGT-3' and antisense, 5'-ATCTGGATGCCCTGGTGGTT-3'; and TβRIII sense, 5'-TACAGAGAGAGGTCACACT-3' and antisense 5'-GTCTTCAGATGCCACACCAG-3'. The total volume used in PCR was 50 μL. PCR products (5 μl) were analyzed by electrophoresis using 1.5% agarose gels and were visualized by SYBR Gold (Molecular Probes, Eugene, USA) staining. All experiments were performed in triplicate.
Protein Preparation and Western Blot Analysis
Protein extracts were prepared using a lysis buffer (RIPA) containing the protease inhibitor PMSF (RIPA:PMSF = 50:1). For Western blot analysis, ~80 μg of protein was separated using 8% SDS-PAGE, which was followed by transfer onto a PVDF membrane (Millipore, USA) and probing with an anti-TβR antibody (1:400, Santa Cruz, USA). The blots were incubated with horseradish-peroxidase-conjugated secondary antibodies (1:5,000) and visualized using an enhanced chemiluminescence detection system (Pierce Biotech Inc., Rockford, IL).
Preparation of Cells Conditioned With the Human TGF-β1 Cytokine
To determine whether TGF-β1 mediates the regulation of the expression of TβRI, TβRII, and TβRIII, we assessed the levels of the TβRs using quantitative real-time PCR and Western blot analysis after treatment with TGF-β1.
TGF-β1 was obtained from Sigma (St. Louis, MO). CAFs or NFs cells were cultured for two consecutive days in medium containing 10% fetal calf serum and were then washed twice with PBS and cultured in serum-free medium containing 10 ng/ml of TGF-β1. After 24 h of treatment, cells were washed and harvested for RNA and protein extraction.
Differences between the groups were statistically evaluated using the unpaired Student's t test. The chi-squared or K Independent Samples Tests were used to compare frequencies, when appropriate. Significance was set at P < 0.05. All analyses were performed using the statistical software SPSS for Windows Version 13 (SPSS Inc., Chicago, USA).
Expression of TβRI, TβRII, and TβRIII in Human OSCC, Oral Leukoplakia, and Normal Tissues
Characteristics of the OSCC Tissue Samples Used for IHC Analysis
Identification of Oral CAFs and NFs
Clinical and Pathological Data of OSCC Samples Used for CAF Cultivation
Well diff. SCC
Well diff. SCC
Mod. diff. SCC
Poor diff. SCC
Mod. diff. SCC
Mod. diff. SCC
Mod. diff. SCC
Loss of TβRII and TβRIII Expression in CAFs Assessed Using RT-PCR and Western Blotting
TGF-β1 Downregulated the Expression of TβRII and TβRIII in Oral CAFs and in NFs
Our results showed that TβRIII and TβRII were significantly downregulated in oral CAFs or in NFs after treatment with 10 ng/ml TGF-β1, with a maximal downregulation at 6-12 h (Figure 5B-G). To assess whether the effects of TGF-β1 on the expression levels of TβRII and TβRIII were specific, we analyzed the role of TGF-β1 in the regulation of TβRI levels in oral CAFs. In contrast with the results obtained for TβRIII and TβRII, TGF-β1 treatment led to a slight increase in the levels of TβRI (this result was not significant) (Figure 5A). Besides, TGF-β1 could also downregulate the TβRIII and TβRII expression in NFs (Figure 6D). These results indicate that transcriptional and translational downregulation associated with increased expression of TGF-β1 in an oral cancer microenvironment (especially in CAFs) may represent a mechanism that leads to oral carcinogenesis. We found that TGF-β1 downregulated TβRII and TβRIII (and not only TβRIII) in oral CAFs and in NFs.
This study represents the first systematic demonstration of the downregulation of the TGF-β receptors TβRII and TβRIII in human OSCC, with approximately 35.3% of OSCC specimens demonstrating low or absent expression of TβRII and approximately 52.9% of specimens demonstrating low or absent expression of TβRIII. This decrease in the expression levels of TβRII and TβRIII correlated with the progression of OSCC. We also demonstrated that loss of TβRII and TβRIII expression was an early event that occurred initially during the OLK stage. However, there was no significant difference in TβRI expression between normal specimens and OLK or OSCC. Thus, we predict that loss of TβRII and TβRIII expression is the most common alteration in the TGF-β signaling pathway described in human OSCC. Studies performed on other tumor tissues regarding TGF-β receptors yielded similar results, and it has been described as having an association with carcinogenesis and tumorprogression [16, 18, 19]. Previous data showed TβRIII can enhance TGFβ-mediated inhibition of proliferation, invasion and angiogenesis. Reexpression of TβRIII in vivo in renal cell carcinoma models induced striking apoptosis . These results were consistent with our current study of tumor progression of oral cancer cells in which TGF-β receptors were defective. The potential mechanism underlying these findings may be that the decreased expression of the two receptors leads to the decrease of TβRII- or TβRIII-mediated apoptosis. These studies, together with the present study, suggest a broad role for both TβRII or TβRIII as tumor suppressors in epithelial-derived malignancies.
Tumor occurrence and development are intrinsically correlated with the role of the surrounding stroma. In the current study, we demonstrated that TβRII and TβRIII played an important role in oral carcinogenesis. Did similar changes take place in tumor-associated stroma? Considering the complex composition of stroma, we chose to study CAFs as the object of our study, as these cells are considered crucial in the process of carcinogenesis. Carcinoma-associated fibroblasts (CAFs) have been regarded as a special kind of myofibroblasts, and they also were named as myofibroblasts in many reports [10, 13, 20, 21]. The stromal microenvironment in human tumours play a key role in the formation of CAFs. This cell-type is mostly defined based on morphological characteristics, biological behavior (including promotion of tumor cell growth)  or the expression of markers such as a-smooth-muscle actin (a-SMA), fibroblast-activated protein (FAP), fibroblast-specific protein-1 (FSP1), neuron-glial antigen-2 (NG2) and PDGF β-receptor . However, and a-SMA was mainly used to identify the CAFs [10, 13, 20, 21]. In our study, the oral CAFs was also detected as expression of a-SMA. To verify our hypothesis, we first isolated and cultured seven primary CAF lines and then assessed the expression levels of TβRI, TβRII, and TβRIII. Coupled with the IHC observations from OSCC, both TβRII and TβRIII were downregulated frequently at the mRNA and protein levels in human oral CAFs compared with NFs. A more pronounced decline was observed for the expression of TβRIII compared with TβRII (11.37 fold vs 2.013 fold). Bacman D et al considered that the decrease of TGF-β receptor expression in stroma as in epithelial tumour tissue might occur via mutation or downregulation . In addition, significant downregulation of TβRII and TβRIII was observed after treatment with TGF-β1 for varying periods. Although we observed a slight increase in TβRI expression, this observation was neither consistent nor significant. The mechanisms underlying the negative regulation mediated by TGF-β1 implicate primarily genes that regulate the cell cycle, including the downregulation of growth-promoting transcription factors, such as c-Myc, ID1, and ID2 . TGF-β isoforms downregulate TβRIII in breast cancer cells; this effect was relatively specific for TβRIII, as it did not affect TβRI and TβRII [19, 23]. However, here we demonstrated the loss of TβRIII and TβRII expression both in CAFs and in NFs after treatment with TGF-β1. The previous report together with our current discoveries lead us to conclude that loss of the expression of TβRIII and/or TβRII in CAFs is a mechanism that underlies the tumor-promoting function of TGF-β1. How might the changes in the cellular characteristics of CAFs, together with the loss of TβRII and TβRIII expression and their response to TGF-β1, affect oral carcinogenesis? The current results prompt us to hypothesize that the increase in the levels of expression of TGF-β during tumor progression stimulates the downregulation of TβRs, both in the tumor itself and in stroma (CAFs), which results in the TβR-mediated reduction of apoptosis. Accordingly, loss of functional TβRII and TβRIII signaling may contribute to apoptotic escape and tumorigenesis.
At present, three main strategies are used to target CAFs during cancer therapy: (a) targeting of the CAF signals that initiate or promote tumor growth, invasion, and metastasis; (b) targeting of the tumor signals that are responsible for the development of "adequate" tumor fibroblasts; and (c) elimination of the CAFs themselves, to abolish all interactions among heterotypic cell types . However, the tumor-host interaction microenvironment is a large and complex network; therefore, it remains questionable whether the use of one single factor (such as antibodies) is efficient in cancer therapy. Two large randomized trials in SCLC failed to show any benefits for inhibitor treatment . Thus, it is necessary to exploit novel strategies that use CAFs as targets in anticancer therapies. In the current study, we demonstrated that the expression of TβRII and TβRIII in oral epithelium and CAFs played an important role in tumorigenesis. In addition, the restoration of the expression levels of TβRII and TβRIII seems more feasible than prior strategies.
Taken together, these data suggest that the loss of the expression of TβRII and TβRIII in oral epithelium and stroma (CAFs) is a common event in OSCC patients. Therefore, we strongly believed that TβRII and/or TβRIII may be used as predictors of tumorigenesis and severity and represent adequate therapeutic targets. However, the understanding of the precise mechanisms involved falls short of what would be required for the development of practical clinical applications. Moreover, the restoration of the expression levels of TβRIII and TβRII in cancerous tissues of the oral mucosa may serve as a novel target for the treatment of oral carcinoma.
The expression of both TβRII and TβRIII was significantly downregulated in oral epithelium and stroma (CAFs) in OSCC. Exogenous TGF-β1 could downregulate both TβRII and TβRIII in oral CAFs and in NFs. Moreover, the restoration of the expression levels of TβRIII and TβRII in cancerous tissues of the oral mucosa may serve as a novel target for the treatment of oral carcinoma.
This study was supported by grants from the National Natural Science Foundation of China (No. 30872873), the Doctoral Fund of the Ministry of Education of China (No. 20070610067).
- Elliott RL, Blobe GC: Role of transforming growth factor Beta in human cancer. J Clin Oncol. 2005, 23: 2078-2093. 10.1200/JCO.2005.02.047.View ArticlePubMedGoogle Scholar
- Attisano L, Wrana JL: Signal transduction by the TGF-beta superfamily. Science. 2002, 296: 1646-1647. 10.1126/science.1071809.View ArticlePubMedGoogle Scholar
- Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE: Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res. 1998, 58: 5329-5332.PubMedGoogle Scholar
- Munoz-Antonia T, Muro-Cacho C, Sharma S, Cantor A, Bepler G: Expression of TGFbeta type-II receptor in association with markers of proliferation and apoptosis in premalignant lung lesions. Cancer. 2007, 110: 1527-1531. 10.1002/cncr.22937.View ArticlePubMedGoogle Scholar
- Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe GC: The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res. 2007, 67: 1090-1098. 10.1158/0008-5472.CAN-06-3117.View ArticlePubMedGoogle Scholar
- Margulis V, Maity T, Zhang XY, Cooper SJ, Copland JA, Wood CG: Type III transforming growth factor-beta (TGF-beta) receptor mediates apoptosis in renal cell carcinoma independent of the canonical TGF-beta signaling pathway. Clin Cancer Res. 2008, 14: 5722-5730. 10.1158/1078-0432.CCR-08-0546.View ArticlePubMedPubMed CentralGoogle Scholar
- Funk GF, Karnell LH, Robinson RA, Zhen WK, Trask DK, Hoffman HT: Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report. Head Neck. 2002, 24: 165-180. 10.1002/hed.10004.View ArticlePubMedGoogle Scholar
- Mincione G, Di Marcantonio MC, Artese L, Vianale G, Piccirelli A, Piccirilli M, Perrotti V, Rubini C, Piattelli A, Muraro R: Loss of expression of TGF-ß1, TßRI, and TßRII correlates with differentiation in human oral squamous cell carcinomas. Int J Oncol. 2008, 32 (2): 323-31.PubMedGoogle Scholar
- Hui P, Shintaniy S, Kim Y, Wong DT: Loss of p12CDK2-AP1 Expression in human oral squamous cell carcinoma with disrupted transforming growth factor-β-Smad signaling pathway. Neoplasia. 2006, 8: 1028-1036. 10.1593/neo.06580.View ArticleGoogle Scholar
- Ostman A, Augsten M: Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Current Opinion in Genetics & Development. 2009, 19: 67-73.View ArticleGoogle Scholar
- Kiaris H, Trimis G, Papavassiliou AG: Regulation of tumor-stromal fibroblast interactions: implications in anticancer therapy. Current Medicinal Chemistry. 2008, 15: 3062-3067. 10.2174/092986708786848596.View ArticlePubMedGoogle Scholar
- Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR: Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999, 59: 5002-5011.PubMedGoogle Scholar
- Orimo A, Gupta PB, Sgrol DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005, 121: 335-348. 10.1016/j.cell.2005.02.034.View ArticlePubMedGoogle Scholar
- Liu Y, Hu T, Shen J, Li SF, Lin JW, Zheng XH, Gao QH, Zhou HM: Separation, cultivation and biological characteristics of oral carcinoma-associated fibroblasts. Oral Dis. 2006, 12: 375-380. 10.1111/j.1601-0825.2005.01207.x.View ArticlePubMedGoogle Scholar
- Bhowmick NA, Neilson EG, Moses HL: Stromal fibroblasts in cancer initiation and progression. Nature. 2004, 432: 332-337. 10.1038/nature03096.View ArticlePubMedPubMed CentralGoogle Scholar
- Bacman D, Merkel S, Croner R, Papadopoulos T, Brueckl W, Dimmler A: TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study. BMC Cancer. 2007, 7: 156-10.1186/1471-2407-7-156.View ArticlePubMedPubMed CentralGoogle Scholar
- Sousa AM, Liu T, Guevara O, Stevens J, Fanburg BL, Gaestel M, Toksoz D, Kayyali US: Smooth muscle alpha-actin expression and myofibroblast differentiation by TGFbeta are dependent upon MK2. J Cell Biochem. 2007, 100: 1581-1592. 10.1002/jcb.21154.View ArticlePubMedPubMed CentralGoogle Scholar
- Gordon KJ, Mei D, Chislock EM, Field TA, Blobe GC: Loss of type III transforming growth factor b receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression. Carcinogenesis. 2008, 29: 252-262. 10.1093/carcin/bgm249.View ArticlePubMedGoogle Scholar
- Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC: The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest. 2007, 117: 206-217. 10.1172/JCI29293.View ArticlePubMedGoogle Scholar
- Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, Ji B, Evans DB, Logsdon CD: Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 2008, 68: 918-926. 10.1158/0008-5472.CAN-07-5714.View ArticlePubMedPubMed CentralGoogle Scholar
- Micke P, Ostman A: Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy?. Lung Cancer. 2004, 45: S163-S175. 10.1016/j.lungcan.2004.07.977.View ArticlePubMedGoogle Scholar
- Kang Y: A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell. 2003, 11: 915-926. 10.1016/S1097-2765(03)00109-6.View ArticlePubMedGoogle Scholar
- Hempell N, How T, Cooper SJ, Green TR, Dong M, Copland JA, Wood CG, Blobe GC: Expression of the type III TGF-b receptor is negatively regulated by TGF-beta. Carcinogenesis. 2008, 29: 905-912. 10.1093/carcin/bgn049.View ArticleGoogle Scholar
- Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, Smylie M, Rubin S, Martins H, Lamont A, et al: Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol. 2002, 20: 4434-4439. 10.1200/JCO.2002.02.108.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/11/88/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.